CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Probiotics daily +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05194033
NCT05194033N/ACompleted
CompareCT.gov

Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)

Peking University·interventional·Posted Jan 18, 2022·Updated Jul 7, 2022

In Brief

A clinical study evaluating Probiotics daily and Placebo daily for SARS-CoV-2. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

Preliminarily explore the effect of oral probiotics in SARS-CoV-2 serum neutralizing antibody titer level and T cell response level (spot formation cell counting). Provide a reference for determining the appropriate oral regimen. Provide necessary parameters for estimating the sample size of confirmatory clinical trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesChina
CollaboratorsCenters for Disease Control and Prevention, China, Beijing Pinggu District Hospital, Peking University Health Science Center Hospital

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJan 18, 2022
Enrollment StartMar 9, 2022
Primary CompletionMay 19, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.5 years ago

Interventions

Probiotics dailydietary

Probiotics 1 time/day for 7 consecutive days

Placebo dailydietary

Placebo 1 time/day for 7 consecutive days